Interleukin-37 expression is increased in chronic HIV-1-infected individuals and is associated with inflammation and the size of the total viral reservoir

Molecular Medicine

Volumn 21, Issue , 2015, Pages 337-345

  Højen, Jesper F ^a   Rasmussen, Thomas A ^a   Andersen, Karen Lise D ^a   Winckelmann, Anni A ^a   Laursen, Rune R ^a   Gunst, Jesper D ^a   Møller, Holger J ^a   Fujita, Mayumi ^b   Østergaard, Lars ^a   Søgaard, Ole S ^a   Dinarello, Charles A ^c,d   Tolstrup, Martin ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD14 ANTIGEN; CD163 ANTIGEN; CD38 ANTIGEN; CYTOKINE; INTERLEUKIN 37; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG; VIRUS DNA; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; IL37 PROTEIN, HUMAN; INTERLEUKIN 1; LEUKOCYTE ANTIGEN; MESSENGER RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE RESPONSE; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; STEADY STATE; T LYMPHOCYTE ACTIVATION; UPREGULATION; BLOOD; GENE EXPRESSION; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; VIROLOGY; VIRUS LOAD;

ADULT; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; GENE EXPRESSION; HIV INFECTIONS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; RNA, MESSENGER; VIRAL LOAD;

EID: 84938849577     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2015.00031     Document Type: Article

References (62)

1. Arend WP. (2002) The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 13:323-40.
2. Novick D, et al. (1999) Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity. 10:127-36.
3. Towne JE, et al. (2011) Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36r, IL-36I, and IL-36,) or antagonist (IL-36Ra) activity. J Biol. Chem. 286:42594-602.
4. Dinarello CA, Bufler P. (2013) Interleukin-37. Semin. Immunol. 25:466-8.
5. Bufler P, Gamboni-Robertson F, Azam T, Kim SH, Dinarello CA. (2004) Interleukin-1 homologues IL- 1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem. J. 381:503-10.
6. Busfield SJ, et al. (2000) Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics. 66:213-6.
7. Kumar S, et al. (2002) Interleukin-1F7B (IL-1H4/ IL-1F7) is processed by caspase-1 and mature IL- 1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine. 18:61-71.
8. Pan G, et al. (2001) IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine. 13:1-7.
9. Smith DE, et al. (2000) Four new members expand the interleukin-1 superfamily. J. Biol. Chem. 275:1169-75.
10. Taylor SL, Renshaw BR, Garka KE, Smith DE, Sims JE. (2002) Genomic organization of the interleukin- 1 locus. Genomics. 79:726-33.
11. Bufler P, et al. (2002) A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc. Natl. Acad. Sci. U. S. A. 99:13723-8.
12. Bulau AM, et al. (2014) Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 111:2650-5.
13. Sharma S, et al. (2008) The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J. Immunol. 180:5477-82.
14. Luo Y, et al. (2013) IL-37, an inhibitor of innate and adaptive immunity, is elevated in the blood of melanoma patients [abstract]. Pigment Cell Melanoma Res. 26:951.
15. Song L, et al. (2012) Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J. Clin. Immunol. 33:111-7.
16. McNamee EN, et al. (2011) Interleukin 37 expres- sion protects mice from colitis. Proc. Natl. Acad. Sci. U. S. A. 108:16711-6.
17. Nold MF, et al. (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 11:1014-22.
18. Fujita H, Inoue Y, Seto K, Komitsu N, Aihara M. (2012) Interleukin-37 is elevated in subjects with atopic dermatitis. J. Dermatol Sci. 69:173-5.
19. Moschen AR, et al. (2011) Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol. Med. 17:840-5.
20. Dinarello CA, Bufler P. (2013) Interleukin-37. Semin. Immunol. 25:466-8.
21. Luo Y, et al. (2013) IL-37 suppresses contact hypersensitivity by inducing tolerogenic dendritic cells. Cytokine. 63:283.
22. Hunt PW. (2012) HIV and inflammation: mechanisms and consequences. Curr. HIV/AIDS Rep. 9:139-47.
23. Neuhaus J, et al. (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J. Infect. Dis. 201:1788-95.
24. Kuller LH, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 5:e203.
25. Currier JS, et al. (2008) Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 118:e29-35.
26. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 370:59-67.
27. Marin B, et al. (2009) Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 23:1743-53.
28. Deeks SG, Phillips AN. (2009) HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 338:a3172.
29. Sogaard OS, et al. (2008) Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish populationbased, nationwide cohort study. Clin Infect. Dis 47:1345-53.
30. Brenchley JM, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12:1365-71.
31. Mavigner M, et al. (2009) HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PloS One. 4:e7658.
32. Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H. (2008) Residual viraemia in HIV-1-infected patients with plasma viral load H 20 copies/ml is associated with increased blood levels of soluble immune activation markers. Scand. J. Immunol. 68:652-60.
33. Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. (2012) Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin. Dev. Immunol. 2012:670957.
34. Kaufmann GR, et al. (2005) Characteristics, determinants, and clinical relevance of CD4 T cell recovery to < 500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin. Infect. Dis. 41:361-72.
35. Piketty C, et al. (1998) Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 12:745-50.
36. Piconi S, et al. (2010) Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS. 24:1991-2000.
37. Baker JV, et al. (2008) Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non- AIDS diseases. J. Acquir. Immune Defic. Syndr. 48:541-6.
38. Gutierrez F, et al. (2008) Patients' characteristics and clinical implications of suboptimal CD4 Tcell gains after 1 year of successful antiretroviral therapy. Curr. HIV Res. 6:100-7.
39. Nakanjako D, et al. (2011) High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect. Dis. 11:43.
40. Lederman MM, et al. (2011) Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J. Infect. Dis. 204:1217-26.
41. Benecke A, Gale M, Jr., Katze MG. (2012) Dynamics of innate immunity are key to chronic immune activation in AIDS. Curr. Opin. HIV AIDS. 7:79-85.
42. Moller HJ, Hald K, Moestrup SK. (2002) Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand. J. Clin. Lab. Invest. 62:293-9.
43. Winckelmann AA, et al. (2013) Administration of a toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PloS One. 8:e62074.
44. Ballak DB, et al. (2014) IL-37 protects against obesity- induced inflammation and insulin resistance. Nature Commun. 5:4711.
45. Llibre JM, et al. (2012) Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir. Ther. 17:355-64.
46. Brenchley JM, Price DA, Douek DC. (2006) HIV disease: fallout from a mucosal catastrophe? Nat. Immunol. 7:235-9.
47. Marchetti G, Tincati C, Silvestri G. (2013) Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin. Microbiol. Rev. 26:2-18.
48. van de Veerdonk FL, et al. (2014) Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37. Front. Microbiol. 5:762.
49. Wiercinska-Drapalo A, Flisiak R, Jaroszewicz J, Prokopowicz D. (2004) Increased plasma transforming growth factor-beta1 is associated with disease progression in HIV-1-infected patients. Viral Immunol. 17:109-13.
50. Garba ML, Pilcher CD, Bingham AL, Eron J, Frelinger JA. (2002) HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells. J. Immunol. 168:2247-54.
51. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. (2012) Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J. Infect. Dis. 206:1558-67.
52. Sandler NG, et al. (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203:780-90.
53. Lien E, et al. (1998) Elevated levels of serumsoluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood. 92:2084-92.
54. Dinarello CA. (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27:519-50.
55. Dinarello CA. (2010) Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 29:317-29.
56. Zeng Q, et al. (2012) Therapeutic potential of interleukin- 37 for suppression of aortic valve inflammatory and osteogenic responses. Circulation. 126:A11803.
57. Cassol E, et al. (2010) Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J. Infect. Dis. 202:723-33.
58. Burdo TH, et al. (2011) Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J. Infect. Dis. 204:154-63.
59. Moller HJ. (2012) Soluble CD163. Scand. J. Clin. Lab. Invest. 72:1-13.
60. Hatano H, et al. (2013) Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J. Infect. Dis. 208:50-6.
61. Poizot-Martin I, et al. (2013) Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years. J. Clin. Virol. 57:351-5.
62. Marchetti G, et al. (2010) Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART. AIDS. 24:1455-60.